DOI 10.2174/0115748863354926250620200719
Prevalence and Impact of Antibodies Against TNF Alpha Inhibitors in Rheumatoid Arthritis and Spondyloarthritis: Systematic Review and Meta-Analysis with Subgroup Analysis.
Аннотация
INTRODUCTION
We aimed to estimate the global prevalence of anti-drug antibodies (ADAb), their impact on treatment response, and associated factors in adults with rheumatoid arthritis (RA) and spondyloarthritis (SpA) treated with TNF alpha inhibitors (TNF-i).
METHODS
We searched PubMed, MEDLINE, Cochrane, Web of Science, and Scopus for observational population-based studies published between January 2010 and September 2021. We included studies reporting ADAb prevalence and their impact on treatment efficacy in adults treated with TNF-i.
RESULTS
The global prevalence of ADAb was 20.8% (95% CI: 6.8-25.5; 95% PI: 6.12-51.42) in RA and 24.8% (95% CI: 19.1-31.5; 95% PI: 7.31-57.98) in SpA. No significant difference in ADAb prevalence was found between infliximab (IFX) and adalimumab (ADA) in RA (p = 0.21) or SpA (p= 0.46). Significant differences were found between IFX and etanercept (ETN) in RA (p<0.0001) and SpA (p=0.001), and between ADA and ETN in RA (p<0.0001) and SpA (p=0.002). For ADA, mean OR was 0.152 (95% CI: 0.054-0.427); for IFX, 0.144 (95% CI: 0.055-0.378); comparison was not significant (p=0.94). By disease, mean OR was 0.149 (95% CI: 0.064-0.347) in RA and 0.303 (95% CI: 0.103-0.890) in SpA; comparison was not significant. Methotrexate use reduced ADAb development in RA and SpA (OR=0.472; 95% CI: 0.324-0.689).
DISCUSSION: These findings confirm the immunogenic potential of TNF-α and support the use of methotrexate co-therapy. ADA and IFX showed similar immunogenicity profiles.
CONCLUSION
ADAb were equally prevalent in RA and SpA. Immunogenicity was associated with treatment response and influenced by the use of methotrexate.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.